{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:26:41Z","timestamp":1648826801773},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00108-017-0323-z","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T12:13:24Z","timestamp":1507896804000},"page":"1332-1340","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moderne, nichtkosmetische Therapie mit Botulinumtoxinen"],"prefix":"10.1007","volume":"58","author":[{"given":"A.","family":"Straube","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"323_CR1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","volume":"15","author":"N Attal","year":"2016","unstructured":"Attal N, de Andrade DC, Adam F et al (2016) Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet Neurol 15:555\u2013565","journal-title":"Lancet Neurol"},{"key":"323_CR2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"PREEMPT 1 Chronic Migraine Study Group, Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793\u2013803","journal-title":"Cephalalgia"},{"key":"323_CR3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/0269215514555036","volume":"29","author":"JA Baker","year":"2015","unstructured":"Baker JA, Pereira G (2015) The efficacy of Botulinum Toxin A on improving ease of care in the upper and lower limbs: a\u00a0systematic review and meta-analysis using the grades of recommendation, assessment, development and evaluation approach. Clin Rehabil 29:731\u2013740","journal-title":"Clin Rehabil"},{"key":"323_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0269215515593609","volume":"30","author":"JA Baker","year":"2016","unstructured":"Baker JA, Pereira G (2016) The efficacy of Botulinum Toxin A for limb spasticity on improving activity restriction and quality of life: a\u00a0systematic review and meta-analysis using the GRADE approach. Clin Rehabil 30:549\u2013558","journal-title":"Clin Rehabil"},{"key":"323_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jvoice.2016.09.022","volume":"31","author":"JP Bradley","year":"2017","unstructured":"Bradley JP, Barrow EM, Hapner ER et\u00a0al (2017) Botulinum toxin \u2013 a dosing trends for adductor spasmodic dysphonia at a\u00a0single institution over 10 years. J\u00a0Voice 31:363\u2013365","journal-title":"J Voice"},{"key":"323_CR6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","volume":"156","author":"E Cernuda-Moroll\u00f3n","year":"2015","unstructured":"Cernuda-Moroll\u00f3n E, Ram\u00f3n C, Mart\u00ednez-Camblor P et al (2015) OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156:820\u2013824","journal-title":"Pain"},{"key":"323_CR7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/mds.21051","volume":"21","author":"C Cordivari","year":"2006","unstructured":"Cordivari C, Misra VP, Vincent A et al (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737\u20131741","journal-title":"Mov Disord"},{"key":"323_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004900.pub2","author":"J Costa","year":"2005","unstructured":"Costa J, Esp\u00edrito-Santo C, Borges A et al (2005) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD004900.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"323_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003633.pub2","author":"J Costa","year":"2005","unstructured":"Costa J, Esp\u00edrito-Santo C, Borges A et al (2005) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD003633.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"323_CR10","doi-asserted-by":"crossref","first-page":"e0162191","DOI":"10.1371\/journal.pone.0162191","volume":"11","author":"C Delorme","year":"2016","unstructured":"Delorme C, Roze E, Grabli D et\u00a0al (2016) Explicit agency in patients with cervical dystonia: altered recognition of temporal discrepancies between motor actions and their feedback. PLOS ONE 11:e162191","journal-title":"PLOS ONE"},{"key":"323_CR11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"PREEMPT 2 Chronic Migraine Study Group, Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804\u2013814","journal-title":"Cephalalgia"},{"key":"323_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/B978-0-444-52137-8.00012-7","volume":"109","author":"V Dietz","year":"2012","unstructured":"Dietz V, Sinkjaer T (2012) Spasticity. Handb Clin Neurol 109:197\u2013211","journal-title":"Handb Clin Neurol"},{"key":"323_CR13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-016-1605-7","volume":"123","author":"V Drinovac Vlah","year":"2016","unstructured":"Drinovac Vlah V, Bach-Rojecky L, Lackovi\u0107 Z (2016) Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain. J\u00a0Neural Transm (Vienna) 123:1403\u20131413","journal-title":"J Neural Transm (Vienna)"},{"key":"323_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004314.pub3","author":"GS Duarte","year":"2016","unstructured":"Duarte GS, Castel\u00e3o M, Rodrigues FB et\u00a0al (2016) Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD004314.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"323_CR15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1474-4422(15)00216-1","volume":"14","author":"JM Gracies","year":"2015","unstructured":"International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group, Gracies JM, Brashear A, Jech R et al (2015) Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a\u00a0double-blind randomised controlled trial. Lancet Neurol 14:992\u20131001","journal-title":"Lancet Neurol"},{"key":"323_CR16","first-page":"299","volume":"6","author":"A Gulamhusein","year":"2012","unstructured":"Gulamhusein A, Mangera A (2012) OnabotulinumtoxinA in the treatment of neurogenic bladder. Biologics 6:299\u2013306","journal-title":"Biologics"},{"key":"323_CR17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C et al (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19:303\u2013308","journal-title":"Mov Disord"},{"key":"323_CR18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders: 3rd edition (beta version). Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"key":"323_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003469.pub4.","author":"BJ Hoare","year":"2010","unstructured":"Hoare BJ, Wallen MA, Imms C et\u00a0al (2010) Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD003469.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"323_CR20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eururo.2012.03.031","volume":"62","author":"Y Ikeda","year":"2012","unstructured":"Ikeda Y, Zabbarova IV, Birder LA et\u00a0al (2012) Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol 62:1157\u20131164","journal-title":"Eur Urol"},{"key":"323_CR21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","volume":"307","author":"JL Jackson","year":"2012","unstructured":"Jackson JL, Kuriyama A, Hayashino Y (2012) Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a\u00a0meta-analysis. JAMA 307:1736\u20131745","journal-title":"JAMA"},{"key":"323_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27072","author":"J Jankovic","year":"2017","unstructured":"Jankovic J (2017) Botulinum toxin: state of the art. Mov Disord. \n                        https:\/\/doi.org\/10.1002\/mds.27072","journal-title":"Mov Disord"},{"key":"323_CR23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s001150050754","volume":"72","author":"S Kelm","year":"2001","unstructured":"Kelm S, Gerats G, Chalkiadaki A, Hefter H (2001) Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 72:302\u2013306 (Article in German)","journal-title":"Nervenarzt"},{"key":"323_CR24","volume-title":"Neue Beobachtungen \u00fcber die in W\u00fcrttemberg so h\u00e4ufig vorfallenden t\u00f6dlichen Vergiftungen durch den Genuss ger\u00e4ucherter W\u00fcrste","author":"J Kerner","year":"1820","unstructured":"Kerner J (1820) Neue Beobachtungen \u00fcber die in W\u00fcrttemberg so h\u00e4ufig vorfallenden t\u00f6dlichen Vergiftungen durch den Genuss ger\u00e4ucherter W\u00fcrste. Osiander, T\u00fcbingen"},{"key":"323_CR25","volume-title":"Das Fettgift oder die Fetts\u00e4ure und ihre Wirkungen auf den thierischen Organismus. Ein Beytrag zur Untersuchung des in verdorbenen W\u00fcrsten giftig wirkenden Stoffes","author":"J Kerner","year":"1822","unstructured":"Kerner J (1822) Das Fettgift oder die Fetts\u00e4ure und ihre Wirkungen auf den thierischen Organismus. Ein Beytrag zur Untersuchung des in verdorbenen W\u00fcrsten giftig wirkenden Stoffes. Cotta\u2019sche Buchhandlung, Stuttgart, T\u00fcbingen"},{"key":"323_CR26","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/09638280701568189","volume":"29","author":"L Kowal","year":"2007","unstructured":"Kowal L, Wong E, Yahalom C (2007) Botulinum toxin in the treatment of strabismus. A review of its use and effects. Disabil Rehabil 29:1823\u20131831","journal-title":"Disabil Rehabil"},{"key":"323_CR27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(15)00222-7","volume":"14","author":"G Kwakkel","year":"2015","unstructured":"Kwakkel G, Meskers CG (2015) Botulinum toxin A for upper limb spasticity. Lancet Neurol 14:969\u2013971","journal-title":"Lancet Neurol"},{"issue":"Suppl 5","key":"323_CR28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1468-1331.2001.00044.x","volume":"8","author":"M Linder","year":"2001","unstructured":"Linder M, Schindler G, Michaelis U et al (2001) Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1\u2011year follow-up using gross motor function measure. Eur J Neurol 8(Suppl 5):120\u2013126","journal-title":"Eur J Neurol"},{"key":"323_CR29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","volume":"116","author":"K M\u00fcller","year":"2009","unstructured":"M\u00fcller K, Mix E, Adib Saberi F et\u00a0al (2009) Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J\u00a0Neural Transm 116:579\u2013585","journal-title":"J Neural Transm"},{"key":"323_CR30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","volume":"67","author":"M Naumann","year":"2013","unstructured":"Naumann M, Dressler D, Hallett M et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon 67:141\u2013152","journal-title":"Toxicon"},{"key":"323_CR31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69:200\u2013235","journal-title":"Pharmacol Rev"},{"key":"323_CR32","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1111\/bph.12763","volume":"171","author":"R Ramachandran","year":"2014","unstructured":"Ramachandran R, Yaksh TL (2014) Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol 171:4177\u20134192","journal-title":"Br J Pharmacol"},{"key":"323_CR33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","volume":"90","author":"J Ramirez-Castaneda","year":"2014","unstructured":"Ramirez-Castaneda J, Jankovic J (2014) Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a\u00a020-year follow-up. Toxicon 90:344\u2013348","journal-title":"Toxicon"},{"key":"323_CR34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1600-0854.2012.01369.x","volume":"13","author":"L Restani","year":"2012","unstructured":"Restani L, Novelli E, Bottari D et\u00a0al (2012) Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic 13:1083\u20131089","journal-title":"Traffic"},{"key":"323_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006499.pub4","author":"FJ Rowe","year":"2017","unstructured":"Rowe FJ, Noonan CP (2017) Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD006499.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"323_CR36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1469-8749.2010.03890.x","volume":"53","author":"U Ryll","year":"2011","unstructured":"Ryll U, Bastiaenen C, De Bie R, Staal B (2011) Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a\u00a0systematic review. Dev Med Child Neurol 53:210\u2013216","journal-title":"Dev Med Child Neurol"},{"key":"323_CR37","volume-title":"S1 Leitlinie Botulismus","author":"AWMF","year":"2012","unstructured":"AWMF (2012) S1 Leitlinie Botulismus. \n                        http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/030-109l_S1_Botulismus_2012-verl%C3%A4ngert.pdf\n                        \n                    . Zugegriffen: 11. Juli 2017"},{"key":"323_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00347-016-0377-7","volume":"114","author":"A Schilimow","year":"2016","unstructured":"Schilimow A, Wiechens B (2016) Medikament\u00f6se Oberlidptosis in der Therapie der rezidivierenden Epitheldefekte infolge neurotropher Keratopathie. Ophthalmologe 114:745. \n                        https:\/\/doi.org\/10.1007\/s00347-016-0377-7","journal-title":"Ophthalmologe"},{"key":"323_CR39","first-page":"924","volume":"12","author":"AB Scott","year":"1973","unstructured":"Scott AB, Rosenbaum A, Collins CC (1973) Pharmacological weakening of extraocular muscles. Invest Ophthalmol 12:924\u2013927","journal-title":"Invest Ophthalmol"},{"key":"323_CR40","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s11255-015-1125-7","volume":"47","author":"Y Sun","year":"2015","unstructured":"Sun Y, Luo D, Tang C et al (2015) The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a\u00a0systematic review and meta-analysis. Int Urol Nephrol 47:1779\u20131788","journal-title":"Int Urol Nephrol"},{"key":"323_CR41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/clinids\/1.4.701","volume":"1","author":"EP Ermengem Van","year":"1979","unstructured":"Van Ermengem EP (1979) Classics in infectious diseases. A new anaerobic bacillus and ist relation to botulism. Rev Infect Dis 1:701\u2013719 (Originally published as \u201eUeber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus\u201c Z Hyg Infektionskrankheiten 26:1\u201356, 1897)","journal-title":"Rev Infect Dis"},{"key":"323_CR42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ene.13133","volume":"24","author":"L Williams","year":"2017","unstructured":"Williams L, McGovern E, Kimmich O et\u00a0al (2017) Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur J Neurol 24:73\u201381","journal-title":"Eur J Neurol"},{"key":"323_CR43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","volume":"46","author":"MA Wollmer","year":"2012","unstructured":"Wollmer MA, de Boer C, Kalak N et\u00a0al (2012) Facing depression with botulinum toxin: a\u00a0randomized controlled trial. J\u00a0Psychiatr Res 46:574\u2013581","journal-title":"J Psychiatr Res"},{"key":"323_CR44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/00207454.2015.1019624","volume":"126","author":"JH Xia","year":"2016","unstructured":"Xia JH, He CH, Zhang HF et\u00a0al (2016) Botulinum toxin A in the treatment of trigeminal neuralgia. Int J Neurosci 126:348\u2013353","journal-title":"Int J Neurosci"},{"key":"323_CR45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1590\/S1677-5538.IBJU.2015.02.05","volume":"41","author":"R Zhang","year":"2015","unstructured":"Zhang R, Xu Y, Yang S et\u00a0al (2015) OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a\u00a0systematic review. Int Braz J Urol 41:207\u2013219","journal-title":"Int Braz J Urol"},{"key":"323_CR46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4103\/0366-6999.154318","volume":"128","author":"X Zhou","year":"2015","unstructured":"Zhou X, Yan HL, Cui YS et al (2015) Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a\u00a0systematic review and meta-analysis. Chin Med\u00a0J 128:963\u2013968","journal-title":"Chin Med J"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-017-0323-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0323-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0323-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T14:08:32Z","timestamp":1511878112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-017-0323-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s00108-017-0323-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,13]]}}}